American College of Gastroenterology Annual Meeting

American College of Gastroenterology Annual Meeting

October 09, 2018
1 min watch

VIDEO: Stelara effective in patients with ulcerative colitis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

PHILADELPHIA – In this exclusive video perspective from the American College of Gastroenterology Annual Meeting, Bruce E. Sands, MD, MS, talks about the research he presented about the efficacy of Stelara in patients with ulcerative colitis.

“This was a study of nearly 1,000 patients,” Sands told Healio Gastroenterology and Liver Disease. “The study was a very positive study that reached its primary outcome of clinical remission.”

The results come from the UNIFI trial, the first study to assess Stelara (ustekinumab, Janssen) in patients with UC who experienced inadequate response to conventional or biologic therapies.

“The safety profile looks consistent with what we’re used to in Crohn’s disease as well,” Sands said. “Overall, this was a highly positive study, and I think will add potentially another great treatment for patients with ulcerative colitis.”

Disclosure: Sands reports financial ties to 4D Pharma, AbbVie, Allergan, Amgen, Arena, Boehringer-Ingelheim, Capella Biosciences, Celltrion Healthcare, EnGene, Ferring, Gilead, Lyndra, Oppilan, Otsuka, Palatin Technologies, Progenity, Protagonist Therapeutics, Rheos Medicines, Seres Therapeutics, Sienne Biopharmaceuticals, Takeda, Theravance, Vivelix, Celgene, Lilly, MedImmune, Millennium, and Pfizer.